Today: 5 April 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
7 January 2026
··
DHT Holdings stock jumps as tanker shares rally on Venezuela oil shake-up

DHT Holdings stock jumps as tanker shares rally on Venezuela oil shake-up

DHT Holdings shares jumped 6.6% to $12.81 in New York as U.S. officials moved to allow Venezuelan crude imports and ease some sanctions. Oil prices slipped, with Brent down 0.7% at $60.31 a barrel. The U.S. Coast Guard seized a Russian-flagged tanker linked to Venezuelan oil after a two-week pursuit. Investors tracked signs of cargo rerouting and upcoming U.S. oil inventory data.
7 January 2026
·····
Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention NEW YORK,

Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention NEW YORK,

Bloom Energy shares jumped 8.1% to $111.38 Wednesday after news of a $600 million credit facility and a $502 million microgrid sale to Quanta. The stock rebounded from an early low of $100.87, trading over 8.3 million shares by late morning. Investors are watching for Bloom’s Feb. 5 earnings and updates on delivery timing and cash use.
7 January 2026
··
Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics shares rose 5.6% to $66.75 after an SEC filing revealed a $100 million upfront payment and low single-digit royalties from Roche and Genentech for a patent license covering oral GLP-1 drugs, including CT-996. The agreement does not affect Structure’s lead candidate, aleniglipron. Full contract details will be disclosed in the annual report.
7 January 2026
·
Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention

Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention

Bloom Energy shares climbed 8.1% to $111.38 Wednesday after news of a $600 million credit line and a $502 million microgrid sale to Quanta. The stock rebounded from an early low of $100.87, with over 8.3 million shares traded by late morning. Investors are watching for Bloom’s Feb. 5 earnings and updates on delivery and cash use. The new bank facility includes leverage and interest-coverage covenants.
7 January 2026
··
Frontline (FRO) stock jumps as Venezuela tanker seizures stir oil-shipping bets

Frontline (FRO) stock jumps as Venezuela tanker seizures stir oil-shipping bets

Frontline shares jumped 7.7% to $23.27 by late morning Wednesday as U.S. authorities seized a Venezuela-linked tanker reflagged under Russia, spurring a rally in tanker stocks. DHT Holdings, International Seaways, Teekay Tankers, and Scorpio Tankers also posted gains. Investors focused on freight rates, which have surged amid sanctions and vessel shortages. Oil prices fell after President Trump announced new Venezuelan crude shipments to the U.S.
7 January 2026
·
Intel stock jumps nearly 9% as CES Panther Lake push meets fresh Wall Street upgrade

Intel stock jumps nearly 9% as CES Panther Lake push meets fresh Wall Street upgrade

Intel shares jumped 8.9% to $43.62 Wednesday after unveiling new Panther Lake laptop chips at CES and receiving an analyst upgrade. The chips, built on Intel’s 18A process, will power over 200 PC models starting Jan. 27. Investors are watching early demand and rollout of the Core Ultra Series 3. J.P. Morgan analysts remain cautious on Intel’s ability to challenge TSMC in advanced chip manufacturing.
7 January 2026
·
Nvidia, AMD or Intel? CES 2026 AI chip rollouts sharpen 2026 stock callsLAS VEGAS,

Nvidia, AMD or Intel? CES 2026 AI chip rollouts sharpen 2026 stock callsLAS VEGAS,

Nvidia CEO Jensen Huang announced the Vera Rubin AI platform is in full production, with servers carrying 72 GPUs and 36 CPUs. AMD introduced MI455 and MI440X chips at CES, targeting AI customers including OpenAI, and previewed a 2027 MI500 series. Analysts’ price targets continue to favor Nvidia and AMD, while Intel’s outlook remains mixed despite a recent upgrade.
7 January 2026
······
Strategy stock jumps on MSCI reprieve for bitcoin-treasury firms — but a key limit stays

Strategy stock jumps on MSCI reprieve for bitcoin-treasury firms — but a key limit stays

MSCI said it will not exclude digital asset treasury companies from its indexes in February 2026, pausing planned changes and opening a broader consultation. Shares of Strategy rose as much as 6% after hours and were last up 3.2% Wednesday morning, before trimming gains as bitcoin fell. MSCI will freeze certain index-weight inputs and halt new additions or size changes for affected stocks.
7 January 2026
·
1 … 284 285 286 287 288 … 584

Stock Market Today

  • Palantir Stock Falls 30% in 2026 as Valuation Concerns Linger
    April 5, 2026, 5:17 AM EDT. Palantir Technologies saw its stock drop about 30% in 2026 after soaring over 600% in the past three years. The company's share price peaked above $200 in late 2025 but has since declined amid concerns about its high valuation. Despite a strong revenue growth of 56% in 2025 and projected growth above 60% for 2026, the stock's price-to-earnings (P/E) ratio remains elevated, falling from 607 in late 2025 to 289 currently, with a forward P/E of 116. The sell-off reflects investor caution over stretched valuations in tech stocks amid economic and regulatory uncertainty, as well as insider sell-offs. Analysts maintain Palantir's stock is overvalued despite solid operational performance.
Go toTop